Certain confidential information contained in this document, marked by [***], has been omitted because AMAG Pharmaceuticals, Inc. (“AMAG”) has determined the information (i) is not material and (ii) would likely cause competitive harm to AMAG or its...Termination Agreement • July 27th, 2020 • Amag Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 27th, 2020 Company Industry JurisdictionThis Termination Agreement (the “Termination Agreement”) contains representations, warranties and covenants that were made only for purposes of the Termination Agreement and as of specific dates; were solely for the benefit of the parties to the Termination Agreement; may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Termination Agreement instead of establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Stockholders of AMAG and other investors and stakeholders are not third-party beneficiaries under the Termination Agreement and should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of AMAG or any of its subsidiaries or affiliates. Mor
TERMINATION AGREEMENTTermination Agreement • July 27th, 2020 • Palatin Technologies Inc • Pharmaceutical preparations • New York
Contract Type FiledJuly 27th, 2020 Company Industry Jurisdiction